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West Nile virus (WNV) is a zoonotic mosquito-transmitted flavivirus that can cause serious disease and death in horses, humans, and birds. WNV is maintained in a transmission cycle between vector mosquitoes and reservoir birds, whereas humans and horses are deadend hosts in nature. In 1999, WNV was introduced to North America, which was its first appearance in the Western hemisphere. Several years later, WNV spread across the United States and throughout North and South America. Migrating birds are considered to be primarily responsible for the rapid expansion of WNV endemic areas (1) . Since WNV is widely distributed throughout many areas of the world (2), WNV infection has become a global public health and veterinary concern. To date, although WNV has not been detected in Japan in nature, the potential for the virus to be introduced by the transportation of WNV-infected vector mosquitoes or reservoir birds from WNV-endemic areas to Japan still exists. Indeed, a study targeting migratory birds revealed a migration route from WNV-endemic areas to Japan (3).
The serological tests for WNV infection, recommended by the manuals and guidelines created by the Japanese Government include a neutralization test and an enzyme-linked immunosorbent assay (ELISA) to measure immunoglobulin M (IgM) antibodies (MAC-ELISA), and both techniques are generally recognized as specific for diagnosing flavivirus infections. However, since WNV is included in the Japanese encephalitis (JE) serological group, as is JE virus (JEV), differential serodiagnosis of WNV infection is problematic, because of the antigenic cross-reactivity between WNV and JEV. In Japan, where JEV is prevalent, most humans and horses have immunity against JEV through vaccination and/or natural infections. To differentiate WNV from JEV infections in horses, our laboratory has developed an epitope-blocking ELISA (4) and a complement-dependent cytotoxicity (CDC) assay (5) . For these assays, we used the nonstructural protein 1 (NS1) of WNV as the antigen. It was previously reported that a commercialized inactivated vaccine, which is licensed for use in horses in the United States and Canada, could induce antibodies to NS1 (6, 7) . Although this vaccine has also been approved in Japan, it is not yet available for practical use. Thus, we considered that an NS1 antibody-based assay was suitable for our study.
The blocking ELISA is based on the binding inhibition of the marker antibody by a competitive antibody included in a test specimen. The CDC assay utilizes the mechanism of antibody-mediated CDC where complement activation triggered by a specific antigen-antibody complex binding to the cell surface causes cell lysis. The former assay, using a WNV-specific monoclonal antibody, has a high specificity, while the latter is a functional assay utilizing cell lysis and is highly sensitive. Therefore, we used the one-point dilution method for the CDC assay for screening and the blocking ELISA for confirming test results.
In this report, these new methods, CDC assay and blocking ELISA, were used to survey antibodies specific for WNV in racehorses residing in Japan. WNV surveillance targeting vector mosquitoes, reservoir birds, and host animals that developed WN fever-or WN encephalitis-like symptoms were performed in preparation for a future threat of WNV introduction in Japan. However, serological survey of antibodies to WNV in dead-end hosts has not been reported in Japan. Since horses are kept outside, it is considered that horsemosquito contact may be more frequent than humanmosquito contact. Thus, we selected horses as a sentinel animal for this survey. We collected 4,000 serum samples obtained from 2-to 5-year-old clinically healthy thoroughbred racehorses residing at the two training centers located in western and eastern Japan. Each year between 2006 and 2010, 800 serum samples were collected from 100 horses in each of 4 age groups at these two locations. All animal experiments were conducted according to the Guidelines for Animal Experimentation at the Equine Research Institute.
First, the CDC assay using a one-point dilution method with a 1:10 dilution of test sera was performed, as previously described (5). Briefly, the procedure consists of three steps: (i) mixing of the test sample with a suspension of WNV NS1-expressing cells, (ii) addition of rabbit complement, and (iii) measurement of lactate dehydrogenase (LDH) activity by adding a chromogenic substrate to the reaction mixture. The cutoff value indicating the presence of WNV NS1 antibodies in the test sera was determined as 19.8z of specific lysis in the CDC assay. Of the 4,000 samples, 48 samples were positive for anti-WNV NS1 antibodies. Second, CDC positive horse sera were tested using the epitope-blocking ELISA, which was performed as described previously (4) . Briefly, microplates were incubated serially with: (i) rabbit serum hyperimmune to NS1 of WNV; (ii) WNV NS1 antigens; (iii) test sera or ELISA diluents; (iv) monoclonal antibody specific for NS1 of WNV; (v) alkaline phosphatase-conjugated goat anti-mouse IgG; and (vi) p-nitrophenyl phosphate. The percentage of monoclonal antibody binding inhibition was calculated on the basis of the absorbances. Sera with 27.6z inhibition or greater were determined to be positive for antibodies to WNV NS1. Of the 48 sera, 17 were positive for WNV-specific NS1 antibodies (Table  1) . There was no significant difference in the number of positive samples between different age groups or locations. The largest number of positives (i.e., 6) was observed in 2009 and 2010, whereas there were 1 or 3 positives in 2006 to 2008. It is highly probable that these positive horses were exposed to WNV infection in the past. However, the other 31 horses found negative for WNV antibodies using the blocking ELISA were positive in the CDC assay, owing to cross-reactivity with antibodies to JEV.
Third, the 17 horses positive for WNV-specific NS1 antibodies were further analyzed by the endpoint methods of CDC assay, MAC-ELISA, and neutralization test with the WNV or JEV antigen. As shown in Table 1 , all individuals showed high neutralizing antibody titers against both WNV and JEV. These results indicate that our strategy using the CDC assay and blocking ELISA is preferable to the neutralization test for serological survey of antibodies to WNV. Although we also tested MAC-ELISA, all horse sera were negative (data not shown). Finally, to determine if the 17 horses were infected with WNV within Japan, we investigated their history of overseas travel. Our results showed that all of the horses were born in the United States, and imported to Japan when they were 2 years old. It was reported that the duration of IgG antibodies against WNV in infected horses was estimated to be at least 15 months (8) . We also estimated that the duration of JEV NS1 antibody in infected horses was 4 years (9). Additionally, in the United States, where WNV is widely distributed, an inactivated vaccine containing NS1 antigen is commercially available for horses. Therefore, the possibility that they were infected or vaccinated outside Japan could not be ruled out in these 17 WNV-positive horses.
The surveillance studies for WNV infection in Japan have reported that no mosquitoes or birds tested positive for WNV RNA up to 2010 (10) (11) (12) . Although the surveillance conducted in 2005-2006 revealed that migratory birds captured in Japan tested positive for antibodies against WNV (3), it was presumed that the birds had not been exposed to WNV in Japan.
In conclusion, we conducted a survey of WNV-specific antibodies in racehorses from 2006 to 2010 in Japan. WNV-specific antibody responses were detected in 17 of 4,000 horses. Since all the WNV-positive horses were born in foreign countries, our survey provided no evidence for WNV invasion into Japan. However, a study revealed that several species of potential WNV vector mosquitoes and reservoir birds are widely distributed in Japan (11) . Therefore, continuous surveillance is required to prepare for a future threat of WNV invasion into Japan.
